Jeong-Woo Oh
Overview
Explore the profile of Jeong-Woo Oh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nam Y, Koo H, Yang Y, Shin S, Zhu Z, Kim D, et al.
Genome Med
. 2023 Mar;
15(1):16.
PMID: 36915208
Background: Although temozolomide (TMZ) has been used as a standard adjuvant chemotherapeutic agent for primary glioblastoma (GBM), treating isocitrate dehydrogenase wild-type (IDH-wt) cases remains challenging due to intrinsic and acquired...
2.
Lee G, Oh J, Her N, Jeong W
Med Image Anal
. 2021 Feb;
70:101995.
PMID: 33640720
In this paper, we propose a novel microscopy image translation method for transforming a bright-field microscopy image into three different fluorescence images to observe the apoptosis, nuclei, and cytoplasm of...
3.
Oh J, Oh Y, Han S, Her N, Nam D
Cancers (Basel)
. 2021 Jan;
13(3).
PMID: 33498427
(1) Background: Recent advances in precision oncology research rely on indicating specific genetic alterations associated with treatment sensitivity. Developing ex vivo systems to identify cancer patients who will respond to...
4.
Han S, Shin H, Lee J, Liu Z, Rabadan R, Lee J, et al.
Exp Mol Med
. 2020 Nov;
52(11):1869.
PMID: 33149237
No abstract available.
5.
Han S, Shin H, Lee J, Liu Z, Rabadan R, Lee J, et al.
Exp Mol Med
. 2019 Dec;
51(12):1-11.
PMID: 31811117
Glioblastoma (GBM) is the most lethal primary brain tumor with few treatment options. The survival of glioma-initiating cells (GICs) is one of the major factors contributing to treatment failure. GICs...
6.
Sa J, Hwang J, Cho Y, Ryu J, Choi J, Jeong S, et al.
Genome Biol
. 2019 Nov;
20(1):253.
PMID: 31771620
Background: Gynecologic malignancy is one of the leading causes of mortality in female adults worldwide. Comprehensive genomic analysis has revealed a list of molecular aberrations that are essential to tumorigenesis,...
7.
Han S, Shin H, Oh J, Oh Y, Her N, Nam D
Cancers (Basel)
. 2019 Nov;
11(12).
PMID: 31771104
Glioblastoma is a highly aggressive and lethal brain tumor, with limited treatment options. Abnormal activation of the neddylation pathway is observed in glioblastoma, and the NEDD8-activating enzyme (NAE) inhibitor, MLN4924,...
8.
Lee M, Kim Y, Lee K, Kang M, Shin H, Oh J, et al.
Cancers (Basel)
. 2019 Aug;
11(8).
PMID: 31370279
As glioblastomas are mostly localized infiltrative lesions, gene therapy based on the retroviral replicating vector (RRV) system is considered an attractive strategy. Combinations of multiple suicide genes can circumvent the...
9.
Lee J, Liu Z, Sa J, Shin S, Wang J, Bordyuh M, et al.
Nat Genet
. 2018 Sep;
50(10):1399-1411.
PMID: 30262818
Outcomes of anticancer therapy vary dramatically among patients due to diverse genetic and molecular backgrounds, highlighting extensive intertumoral heterogeneity. The fundamental tenet of precision oncology defines molecular characterization of tumors...
10.
Her N, Oh J, Oh Y, Han S, Cho H, Lee Y, et al.
Cell Death Dis
. 2018 Jul;
9(8):792.
PMID: 30022047
Testing new ways to identify untapped opportunities for glioblastoma therapies remains highly significant. Amplification and overexpression of MDM2 gene is frequent in glioblastoma and disrupting the MDM2-p53 interaction is a...